Scoping Review of Epigenetics on Neurodegenerative Diseases: Research Frontiers and Publication Status

Overview

Journal Front Neurosci

Date 2024 Oct 24

PMID 39445078

Authors

Yanyan Zhang

Yukang Mao

Qiangqiang Fu

Xiaoguang Zhang

Dong Zhang

Yunhua Yue

Chuanxi Yang

Affiliations

Soon will be listed here.

Abstract

Aims: Epigenetics has significantly evolved and emerged as important players in the pathogenesis of neurodegenerative diseases. However, a scientometric synthesis of such changes over time is currently lacking.

Methods: We conducted a comprehensive search of the Web of Science Core Collection from inception until November 5, 2022, using appropriate keywords. Our primary objective was to employ scientometric analysis to depict changes in keywords over time and to assess the structure and credibility of clusters. Additionally, we examined the network of research (countries, institutions, and authors) using CiteSpace and VOSviewer.

Results: We identified 25 clusters with well-structured networks ( = 0.82) and highly credible clustering ( = 0.91) from 16,181 articles published between 1999 and 2022. Our findings are as follows: (a) the literature and research interest concerning the epigenetics of neurodegenerative diseases are continuously growing; (b) the three most productive countries are the USA, China, and Germany; (c) international collaborative relationships exist, alongside small, isolated collaboration networks of individual institutions.

Conclusion: The number and impact of global publications on the epigenetics of neurodegenerative diseases have expanded rapidly over the past 20 years. This review provides valuable guidelines for researchers interested in neurodegenerative diseases research.

References

Lambert J, Ibrahim-Verbaas C, Harold D, Naj A, Sims R, Bellenguez C . Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013; 45(12):1452-8. PMC: 3896259. DOI: 10.1038/ng.2802. View

Juzwik C, Drake S, Zhang Y, Paradis-Isler N, Sylvester A, Amar-Zifkin A . microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog Neurobiol. 2019; 182:101664. DOI: 10.1016/j.pneurobio.2019.101664. View

Salvatori B, Biscarini S, Morlando M . Non-coding RNAs in Nervous System Development and Disease. Front Cell Dev Biol. 2020; 8:273. PMC: 7218086. DOI: 10.3389/fcell.2020.00273. View

Leggio L, Vivarelli S, LEpiscopo F, Tirolo C, Caniglia S, Testa N . microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. Int J Mol Sci. 2017; 18(12). PMC: 5751299. DOI: 10.3390/ijms18122698. View

Nakagawa S, Samarasinghe G, Haddaway N, Westgate M, ODea R, Noble D . Research Weaving: Visualizing the Future of Research Synthesis. Trends Ecol Evol. 2018; 34(3):224-238. DOI: 10.1016/j.tree.2018.11.007. View

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Junker A, Krumbholz M, Eisele S, Mohan H, Augstein F, Bittner R . MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009; 132(Pt 12):3342-52. DOI: 10.1093/brain/awp300. View

Zhang M, He P, Bian Z . Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers. Front Mol Neurosci. 2021; 14:685143. PMC: 8371338. DOI: 10.3389/fnmol.2021.685143. View

Song Y, Zhu X, Zhang X, Xiong H . Targeted Mitochondrial Epigenetics: A New Direction in Alzheimer's Disease Treatment. Int J Mol Sci. 2022; 23(17). PMC: 9456144. DOI: 10.3390/ijms23179703. View

10.

Cha D, Mengel D, Mustapic M, Liu W, Selkoe D, Kapogiannis D . miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer's Patients. Front Neurosci. 2019; 13:1208. PMC: 6902042. DOI: 10.3389/fnins.2019.01208. View

11.

Lunnon K, Smith R, Hannon E, De Jager P, Srivastava G, Volta M . Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nat Neurosci. 2014; 17(9):1164-70. PMC: 4410018. DOI: 10.1038/nn.3782. View

12.

Alvarez-Erviti L, Seow Y, Schapira A, Gardiner C, Sargent I, Wood M . Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011; 42(3):360-7. PMC: 3107939. DOI: 10.1016/j.nbd.2011.01.029. View

13.

Lopez-Otin C, Blasco M, Partridge L, Serrano M, Kroemer G . The hallmarks of aging. Cell. 2013; 153(6):1194-217. PMC: 3836174. DOI: 10.1016/j.cell.2013.05.039. View

14.

Lau P, Bossers K, Janky R, Salta E, Sala Frigerio C, Barbash S . Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med. 2013; 5(10):1613-34. PMC: 3799583. DOI: 10.1002/emmm.201201974. View

15.

Wang W, Rajeev B, Stromberg A, Ren N, Tang G, Huang Q . The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008; 28(5):1213-23. PMC: 2837363. DOI: 10.1523/JNEUROSCI.5065-07.2008. View

16.

Levine M, Lu A, Quach A, Chen B, Assimes T, Bandinelli S . An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018; 10(4):573-591. PMC: 5940111. DOI: 10.18632/aging.101414. View

17.

Hu W, Zhang G, Zhou Y, Xia J, Zhang P, Xiao W . Recent development of analytical methods for disease-specific protein -GlcNAcylation. RSC Adv. 2023; 13(1):264-280. PMC: 9768672. DOI: 10.1039/d2ra07184c. View

18.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View

19.

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood M . Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4):341-5. DOI: 10.1038/nbt.1807. View

20.

Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman P, Rogers J . Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging. 2009; 31(12):2025-37. PMC: 2962691. DOI: 10.1016/j.neurobiolaging.2008.12.005. View